Scilex (NASDAQ:SCLX - Get Free Report) is projected to post its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect Scilex to post earnings of ($0.10) per share and revenue of $17.87 million for the quarter.
Scilex (NASDAQ:SCLX - Get Free Report) last issued its quarterly earnings results on Friday, January 17th. The company reported ($0.18) earnings per share for the quarter. On average, analysts expect Scilex to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Scilex Trading Up 7.0 %
Shares of SCLX stock traded up $0.02 during trading hours on Friday, reaching $0.35. 1,162,829 shares of the company's stock were exchanged, compared to its average volume of 1,405,610. Scilex has a 1 year low of $0.21 and a 1 year high of $2.30. The stock has a market cap of $84.33 million, a PE ratio of -0.42 and a beta of 1.15. The stock's fifty day moving average price is $0.39 and its two-hundred day moving average price is $0.69.
Analysts Set New Price Targets
Separately, D. Boral Capital restated a "buy" rating and set a $22.00 price target on shares of Scilex in a research note on Friday, February 28th.
View Our Latest Analysis on Scilex
Scilex Company Profile
(
Get Free Report)
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Further Reading
Before you consider Scilex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scilex wasn't on the list.
While Scilex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
